Please select the option that best describes you:
Does a complete pathologic response to neoadjuvant chemotherapy affect the duration of endocrine therapy/OFS that you recommend for a premenopausal patient with HR+/Her2+ breast cancer?
Answer from: Medical Oncologist at Academic Institution
This is a great question. In my practice, I do not alter duration of endocrine therapy based on response to chemo. Luminal tumors less commonly achieve pCR, and degree of response to neoadjuvant chemotherapy is less reliable as a prognostic factor in luminal tumors compared to TNBC and HER2+ tumors....
Sign in or Register to read more